Navigation Links
Osteopontin: a useful biomarker in asbestos-related cancer

Pleural mesothelioma is an asbestos-related cancer that invades the chest cavity and the lining of the lungs. Workers at risk for high levels of exposure are miners, factory workers, carpenters, electricians//, ship fitters, ships' electricians, boilermakers, insulation manufacturers, railroad workers, gas-mask manufacturers, and pipe insulators.

Recently, a study, published in the October 13 issue of New England Journal of Medicine, was conducted to test the hypothesis that osteopontin is a useful biomarker in pleural mesothelioma and, more specifically, to compare serum levels of osteopontin in a cohort of subjects with asbestos-related biomarker disease with preoperative levels in patients with surgically treated pleural mesothelioma. Osteopontin is a glycoprotein that is over expressed in lung, breast, colorectal, gastric, and ovarian cancer and in melanoma. High levels of osteopontin have previously been shown to correlate with tumor invasion, progression, and metastases.

The researchers investigated the presence of osteopontin in pleural mesothelioma and determined serum osteopontin levels in three populations: subjects without cancer who were exposed to asbestos, subjects without cancer who were not exposed to asbestos, and patients with pleural mesothelioma who were exposed to asbestos.

For the study, a group of 69 subjects with asbestos-related nonmalignant pulmonary disease were compared with 45 subjects without exposure to asbestos and 76 patients with surgically staged pleural mesothelioma. Tumor tissue was examined for osteopontin by immunohistochemical analysis, and serum osteopontin levels were measured by an enzyme-linked immunosorbent assay.

Serum osteopontin levels were found to be significantly higher in the group with pleural mesothelioma than in the group with exposure to asbestos. Immunohistochemical analysis revealed osteopontin staining of the tumor cells in 36 of 38 samples of pleural mesothelioma.
Data from this study suggest that serum osteopontin levels could be used to discriminate between persons with exposure to asbestos who do not have early pleural mesothelioma and those with exposure to asbestos who do have early pleural mesothelioma, regardless of the histologic type of the mesothelioma.

The authors point out that the most important result of this study is the apparent ability of an enzyme-linked immunosorbent assay (ELISA) for osteopontin to identify early pleural mesothelioma (stage I). Also, the finding that osteopontin was present in the tumor cells of pleural mesothelioma and not in the stroma provides support for the specificity of osteopontin as a marker for transformed mesothelial cells. This finding, if confirmed, would have immediate clinical applications, because the use of therapy could potentially influence survival among patients with stage I pleural mesothelioma.
'"/>




Related medicine news :

1. ATG useful in transplant patients as substitute for steroids
2. Vitamin E useful for Alzheimers
3. Carboplatin, Lung cancer drug may be useful in treating breast tumor
4. Vitamin B12 can help in detecting cancers
5. Want skin cancer? Please have a cigarette
6. New hope for cancer victims – will vaccine cure the deadly bug
7. Clintons new problem - Is the outgoing American president suffering from skin cancer?
8. Are cancer patients being taken for a ride?
9. Breast cancer treatment to be determined by gene test
10. Ductal lavage may detect early breast cancer
11. Beware of the oral patch! It could be cancer!!!
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/16/2017)... Louis, MO (PRWEB) , ... January 16, 2017 , ... St. Louisans are well-aware of ... here , This year’s influenza shot seems to be having no effect on ... area, at least half of the people around are coughing, sneezing, or sniffling ...
(Date:1/16/2017)... CITY, UT (PRWEB) , ... January 16, 2017 , ... ... disease not only to treat, but to test for, as well. The money spent ... billion every year.(1) Doctors in the U.S. screen patients for cancer more than in ...
(Date:1/15/2017)... York, NY (PRWEB) , ... January 15, 2017 , ... ... strategic accounts in the United States for the asthma & allergy friendly mark. This ... America to independently test and identify consumer products to be more suitable for the ...
(Date:1/15/2017)... ... January 15, 2017 , ... "On Tour is a music themed slideshow ... ease," said Christina Austin - CEO of Pixel Film Studios. , On Tour’s ... the style and animation of their slideshows. Place each slide on top of another ...
(Date:1/15/2017)... ... January 15, 2017 , ... The ... is pleased to announce that it will be assisting HackensackUMC Mountainside with its ... Glen Ridge townships, servicing all surrounding towns. The firm will be working closely ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... -- This morning, Stock-Callers.com draws attention to ... at yesterday,s closing bell: Clovis Oncology Inc. (NASDAQ: ... GALE ), and ACADIA Pharmaceuticals Inc. (NASDAQ: ... to develop technologies and products that combat debilitating and ... use less and cleaner energy, and provide safer, cleaner ...
(Date:1/13/2017)... -- The 2016 election resulted in a big ... in favor of legalizing cannabis for recreational use, including ... U.S. In addition, the state of Colorado ... sales. The ArcView Group has published an updated research report ... in the U.S. last year reached $6.7 billion, a growth of ...
(Date:1/13/2017)... NEW YORK , Jan. 12, 2017 /PRNewswire-USNewswire/ ... type 1 diabetes (T1D) research, is pleased to ... advocacy efforts, the Centers for Medicare & Medicaid ... devices approved by the FDA for use in ... a significant step toward making them eligible for ...
Breaking Medicine Technology: